Bemotrizinol (bis-ethylhexyloxyphenol methoxyphenol triazine), a broad-spectrum, organic ultraviolet (UV) filter that has been available in Europe since 2000, is the first new active ingredient with broad availability to be added to the FDA's OTC sunscreen monograph in more than 25 years, and the first organic UV filter to be generally recognized as safe and effective (GRASE). Data with other organic UV filters are insufficient for a GRASE designation.
ULTRAVIOLET RADIATION ― UV radiation is classified based on wavelength as UVB (290-320 nm), UVA2 (320-340 nm), or UVA1 (340-400 nm). UVB, which is mostly...
- Ensitrelvir (Xocova) for Post-Exposure Prophylaxis of COVID-19
- Omidenepag Isopropyl (Omlonti) for Glaucoma
- In Brief: New Warning for OTC Orlistat (Alli)
- OTC Differin Epiduo Gel for Acne
- Drugs for Hypertriglyceridemia
- Sonrotoclax (Beqalzi) for Mantle Cell Lymphoma
- Vepdegestrant (Veppanu) for Advanced Breast Cancer
ISSUE
The FDA has approved the oral interleukin (IL)-23 receptor antagonist icotrokinra (Icotyde – Janssen) for treatment of moderate to severe plaque psoriasis in patients ≥12 years old who are candidates for systemic treatment or phototherapy. Icotrokinra is the first oral targeted interleukin blocker to become available in the US.
STANDARD TREATMENT — Oral drugs for management of moderate to severe plaque psoriasis include methotrexate, cyclosporine (Neoral, and others), the phosphodiesterase type-4 inhibitor apremilast (Otezla, Otezla XR), the retinoid acitretin, and the tyrosine kinase 2 inhibitor deucravacitinib (Sotyktu). Low-dose methotrexate is effective and inexpensive, but it increases the risk of infection and can cause serious hematologic and hepatic adverse effects. Use of cyclosporine for >1 year is not recommended because of the risk of …